A study analyzes the effects of homelessness on childbirth; some states report drops in demand for COVID-19 vaccines; researchers examine long-term risks of severe COVID-19.
New research published in JAMA Network Open shows women who experienced homelessness were more likely to experience preterm labor and incur higher delivery-associated costs compared with women with steady housing who had a delivery and were admitted to the same hospital. The cross-sectional study included over 15,000 pregnant women experiencing homelessness and 308,242 pregnant women with steady housing who had their births in hospitals in Florida, Massachusetts and New York in 2014. The wide disparities in delivery-associated outcomes highlight the importance of health care professionals screening for homelessness during prenatal care visits, researchers concluded.
Louisiana, Kansas, and Mississippi have all seen drops in demand for COVID-19 vaccines, according to the Associated Press. In Iowa too, about half of counties have stopped asking for new doses from the state. With supply of the vaccines outpacing demand in some states due to low interest in the shots, officials are turning down shipments from the federal government. The low demand puts the United States in a tricky position as it now has tens of thousands of unused COVID-19 vaccine doses in store while other countries like India and Brazil face dire medical emergencies. Over 200 million doses have been administered in the United States, and over half of all US adults have received at least 1 dose.
A study published in Nature found that individuals who suffered severe infections of COVID-19 are at greater risk of long-term complications, NPR reports. Using data from the US Department of Veterans Affairs to assess health outcomes of over 73,000 people who had COVID-19 who were not hospitalized, researchers compared outcomes with nearly 5 million users who did not have COVID-19 and were not hospitalized. After 6 months, those who had COVID-19 were at a greater risk of new onset heart disease, diabetes, mental health disorders, substance use disorders, and kidney disease, among other problems. However, it is difficult for investigators to determine which outcomes are a direct consequence of infection and which are indirect.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More